Breath Analysis for the Detection of Invasive Fungal Infections
Key facts
- Where
- Zurich, SwitzerlandSee the site
Where in Switzerland
- University Hospital of ZurichZurich, SwitzerlandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Zurich
- Trial code
- NCT06537726
- Record updated
- 10 April 2025
- Original description
Patients with leukemia and concomitant neutropenia are at high risk of developing invasive fungal infections (IFI) that are associated with high morbidity and mortality. As these patients typically have severe thrombocytopenia, direct diagnostic sampling with invasive procedures is often not possible due to the high peri-interventional risk. Therefore, the presumptive diagnosis of IFI is primarily based on compatible lung findings on computed tomography and serologic detection of fungal cell wall components, which, however, have limited sensitivity and specificity.Read full original descriptionShow less
Real-time Breath Analysis for the Detection of Invasive Fungal Infections in Neutropenic High-risk Patients
Patients with leukemia and concomitant neutropenia are at high risk of developing invasive fungal infections (IFI) that are associated with high morbidity and mortality. As these patients typically have severe thrombocytopenia, direct diagnostic sampling with invasive procedures is often not possible due to the high peri-interventional risk. Therefore, the presumptive diagnosis of IFI is primarily based on compatible lung findings on computed tomography and serologic detection of fungal cell wall components, which, however, have limited sensitivity and specificity.
With the present study, the investigators aim to determine a set of specific volatile biomarkers in leukemia patients with proven or probable IFI using secondary electrospray ionization high-resolution mass spectrometry (SESI-HRMS).
Inclusion: Diagnosis of acute leukemia; Planned chemotherapy with a duration of hospitalisation of 2 weeks or longer; Neutropenia (<500/µl) present at inclusion or planned chemotherapy with expected neutropenia (<500/µl) for more than 7 days.
Exclusion: Unable to follow instructions for breath analysis; Anatomic abnormalities precluding the use of a mouthpiece for breath analysis.